fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

scPharmaceuticals Inc. has resubmitted its NDA to the FDA for Furoscix for the treatment of congestion in patients with heart failure.

Written by | 2 Jul 2020

scPharmaceuticals Inc. announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the FDA seeking approval of Furoscix (subcutaneous furosemide) for the treatment of congestion in… read more.

RM 493 filed with MAA for pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity.- Rhythm Pharma

Written by | 2 Jul 2020

Rhythm Pharmaceuticals announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for RM 493 (setmelanotide) for the treatment of pro-opiomelanocortin (POMC)… read more.

Preliminary data shows that BNT 162b1 is safe and immunologically active in COVID-19.- Pfizer and BioNTech

Written by | 2 Jul 2020

Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT 162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2. The BNT… read more.

Ertugliflozin preserves renal function in Type 2 diabetes with albuminuria

Written by | 2 Jul 2020

Article written by Bruce Sylvester In a study published on June 2, 2020 in Diabetologia, researchers reported that ertugliflozin preserves renal function in type 2 diabetics with baseline… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.